Passage Bio Holds Special Stockholder Meeting
Bitget2026/11/06 11:11- Passage Bio shareholders approved merger-related share issuance to Remix Therapeutics securityholders at a November 5, 2026, special meeting.
- Stockholders authorized a reverse stock split ranging from 1-for-2 to 1-for-10, with the final ratio subject to mutual agreement.
- The restated charter won approval, including a name change to Remix Therapeutics effective at the second merger’s effective time.
- All nonbinding charter proposals passed, covering the name change, voting requirements and other governance provisions.
- Shareholders adopted the 2026 Equity Incentive Plan and Employee Stock Purchase Plan, effective upon completion of the first merger.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic IPO frenzy! Subscription demand several times oversubscribed, targeting a valuation of 1.4 trillions USD
Anthropic's upcoming IPO has sparked strong market enthusiasm, with subscription demand reaching several times the offering. The company plans to raise up to 90.4 billions USD through the IPO and private placement, potentially setting a new record for the largest listing in history. Although its valuation target of 1.4 trillions USD is slightly lower than previously expected, the market response remains extremely enthusiastic, fueled by robust institutional anchor demand.
BUZZ-Satellogic shares surge on strong third-quarter results
Crypto prices
More
